Estimated difference in mean between trial arms for secondary outcomes, in total and stratified by prognostic group
| All participants | Prognostic group | |||||||
|---|---|---|---|---|---|---|---|---|
| Minimal / mild | Moderate | Severe | ||||||
| Difference in mean outcome (95% CI)a | P-value | Difference in mean outcome (95% CI)a | P-value | Difference in mean outcome (95% CI)a | P-value | Difference in mean outcome (95% CI)a | P-value | |
| Anxiety symptom severity (GAD-7) | ||||||||
| Total analysed, n | 1780 | — | 1285 | — | 278 | — | 217 | — |
| 3 months | −0.43 (−0.99 to 0.12) | 0.13 | 0.10 (−0.50 to 0.70) | 0.74 | −1.17 (−2.63 to 0.28) | 0.11 | −1.18 (−2.99 to 0.63) | 0.20 |
| 12 months | −0.17 (−0.78 to 0.45) | 0.59 | 0.0005 (−0.66 to 0.66) | 0.99 | 0.13 (−1.55 to 1.80) | 0.88 | −0.13 (−2.19 to 1.94) | 0.91 |
| Mental health self-efficacy (MHSES) | ||||||||
| Total analysed, n | 1779 | — | 1284 | — | 278 | — | 217 | — |
| 3 months | 1.39 (0.31 to 2.46) | 0.01 | 1.06 (−0.15 to 2.27) | 0.09 | 2.35 (−0.22 to 4.91) | 0.07 | 1.55 (−2.10 to 5.20) | 0.41 |
| 12 months | 0.87 (−0.43 to 2.17) | 0.19 | 0.49 (−0.88 to 1.86) | 0.48 | 1.10 (−2.53 to 4.73) | 0.55 | 1.20 (−3.62 to 6.02) | 0.63 |
| Quality of life (AQoL-8D) | ||||||||
| Total analysed, n | 1761 | — | 1270 | — | 277 | — | 214 | — |
| 3 months | 0.011 (−0.005 to 0.027) | 0.16 | 0.0005 (−0.017 to 0.019) | 0.96 | 0.047 (0.007 to 0.088) | 0.02 | 0.033 (−0.010 to 0.075) | 0.13 |
| 12 months | 0.013 (−0.007 to 0.033) | 0.19 | 0.010 (−0.013 to 0.033) | 0.39 | 0.014 (−0.039 to 0.067) | 0.60 | 0.028 (−0.037 to 0.093) | 0.40 |
↵a Estimated using linear mixed-effects regression with random intercepts for individuals and adjusted for baseline outcome measure, general practice, time, and prognostic group (for all participants only); mean outcome is constrained to be equal at baseline. AQoL-8D = Assessment of Quality of Life Instrument. GAD-7 = 7-item Generalised Anxiety Disorder scale. MHSES = Mental Health Self-Efficacy Scale.